Trial Details

RECRUITING
Basic Information
Clinical ID c1144
Identifier NCT05784246
Trial Title A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis
Trial URL Visit Original Page
Study Information
Study Results

NO

Conditions Ulcerative Colitis
Interventions DRUG: Mirikizumab IV|DRUG: Mirikizumab SC
Participant Information
Sponsor Eli Lilly and Company
City San Diego
Country/Region United States
Enrollment Criteria
Sex Requirement ALL
Age Requirement CHILD
Study Design
Study Type INTERVENTIONAL
Phase PHASE3
Time Information
Start Date 2023-11-22
Primary Completion Date 2025-07-26
Completion Date 2025-03-27